Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma

Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma

The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of frontlin...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander Meisel, Ziad Kassem, Daniel Turek, Tanja Angelina Gradistanac, Tristan de Lage, Christina Züger
Format: Article
Language:English
Published: THE HEALTHBOOK COMPANY LTD. 2025-03-01
Series:healthbook TIMES. Oncology Hematology
Online Access:https://doi.org/10.36000/HBT.OH.2025.23.174
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items